Abstract
This paper discusses a research protocol based on a clinical trial on patients diagnosed by Fibroscan with cirrhosis class A on the Child-Pugh score without complications related to portal hypertension. In this protocol, these patients would receive a set of four drugs (Carvedilol, Atorvastatin, Spironolactone, Isosorbide Dinitrate) that inhibit pathophysiological pathways causing complications related to portal hypertension. Through the administration of the above-mentioned drugs, cirrhotic class-A patients can potentially be able carry on with their lives in the same way a non-cirrhotic patient would, hypothetically presenting a cure to cirrhosis.
Details
Presentation Type
Paper Presentation in a Themed Session
Theme
2020 Special Focus—Advancing Health and Equity: Best Practices in an International Perspective
KEYWORDS
Gastroenterology, Hepatology, Cirrhosis
Digital Media
This presenter hasn’t added media.
Request media and follow this presentation.
